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Clozapine-induced liver injuryand pleural effusion 
Joseph P.M. Kane, Francis A. O’NeillCentre for Public Health, Institute ofClinical Sciences, Queens UniversityBelfast Royal Victoria Hospital, UK
Abstract
Clozapine, whilst associated commonly with
a transient and benign increase in liver
enzymes, has also been associated with vary-
ing presentations of hepatitis in existing case
reports. This report describes what we believe
to be the first documented case of acute liver
injury and pleural effusion associated with
clozapine, resolving after cessation of the
agent. The case supports existing literature in
advocating a high index of suspicion, particu-
larly in the 4-5 weeks following clozapine initi-
ation, when considering nonspecific clinical
symptoms and signs.
Introduction
Clozapine is an atypical antipsychotic and a
highly effective agent in the management of
treatment resistant schizophrenia.1 Whilst
associated commonly with a transient and
benign increase in liver enzymes,2 it also lists
hepatitis amongst its side effects. Existing
case studies report a wide variation in comor-
bid characteristics and biochemical profiles of
such presentations. In this case study we
describe a case of clozapine-induced hepato-
toxicity with associated pleural effusion.
Case Report
Ms. A, a 47-year-old woman with a long-
standing diagnosis of schizophrenia, was com-
menced on clozapine therapy having suffered a
relapse characterized by an escalation in audi-
tory hallucinations, persecutory thought,
behavioral disturbance and negative symp-
toms; treatment with both atypical (olanzap-
ine, risperidone) and typical (haloperidol)
antipsychotic agents had been unsuccessful.
No significant medical disorders were present
in the patient’s past medical history or family
history, nor was there a history of drug aller-
gies. There was no history of alcohol or illicit
drug abuse. She described a smoking history
of 30 pack years. Baseline electrocardiograph
and blood tests, including liver function tests
(LFTs), full blood count, fasting lipid profile
and glucose, were all unremarkable.
Daily clozapine dose was titrated to 400 mg
over a three week period with mild sedation
alone noted as a side effect. A tangible
improvement in MsA’s mental state was noted
over this period, with improvement in both
positive and negative symptoms.
Thirty days following clozapine prescription,
the patient developed lethargy and pyrexia,
cough and left basal crepitations. Blood inves-
tigations revealed an elevated white cell count
(WCC 14.4×109/L), characterized by
eosinophilia (2.39×109/L), and elevated C
reactive protein (CRP). LFTs returned
deranged values of bilirubin 23 umol/L (normal
range 3-18 umol/L), alkaline phosphatase
(ALP) 220 U/L (n.r. 35-120 U/L), aspartate
transaminase (AST) 338 U/L (n.r. 4-32),
gamma-glutamyl transpeptidase (GGT) 96 U/L
(n.r. 12-58 U/L), and alanine transaminase
(ALT) 894 U/L (n.r. 10-35 U/L). 
Symptoms persisted for several days, during
which chest X-ray indicated the presence of a
small left basal effusion. Although initially
diagnosed as a lower respiratory chest infec-
tion and treated with Co-amoxiclav, clar-
ithromycin, and subsequently piperacillin/
tazobactam, all antibiotic agents were discon-
tinued seven days after onset of symptoms
when concern arose that the agents were both
ineffective and contributing to LFT derange-
ment. 
Abdominal ultrasound was normal, while
copper and caeruloplasmin levels were within
reference ranges. Hepatitis A,B,C and E serol-
ogy tests were negative, as were CMV and EBV
serology. Levels of serum immunoglobulins
and autoantibodies [(antinuclear antibodies
(ANA), anti-smooth muscle antibodies
(ASMA), anti-liver-kidney microsome-1 anti-
bodies (ALKM-1) and anti-liver cytosol anti-
body-1 (ALC-1)] were within reference ranges
and serum paracetamol levels were measured
at less than 0.1 mmol/L. Whilst magnetic reso-
nance imaging studies and pleural effusion
aspiration were scheduled, these were pre-
cluded by the patient withholding her consent
to undergo these investigations.  
The patient deteriorated clinically over the
following days, developing jaundice and per-
sisting lethargy. Liver enzymes reached peak
values of bilirubin 86 umol/L, ALP 406 U/L, AST
569 U/L, GGT 173 U/L, and ALT 707 U/L before
clozapine was discontinued, 40 days following
initial prescription. Liver enzymes reduced
markedly from two days after cessation,
returning to within normal reference ranges
within six weeks. All evidence of pleural effu-
sion had disappeared from chest x-ray within
two days of clozapine cessation.
Discussion and Conclusions
We report a case of drug-induced liver injury
with pleural effusion as a side effect of clozap-
ine therapy. Although transient LFT elevation
is well recognized in the period following
clozapine prescription,2 liver injury is a rare
side effect of clozapine therapy; to date only
five cases of mortality secondary to hepatic
failure associated with clozapine therapy have
been reported in the United Kingdom.3
Current guidelines, however, advocate routine
LFT monitoring only at baseline and every six
months following prescription.
Other cases of drug-induced liver injury
have been described in the existing litera-
ture,4-8 though none with associated pleural
effusion. Whilst Thompson et al. 9 describe a
case involving hepatitis and bilateral pleural
effusion, together with hematuria and protein-
uria, insult was of an obstructive, rather than
hepatocellular mechanism, and symptoms
occurred far earlier in the course of treatment
(18 days).9
Two distinct mechanisms for such reactions
arise from the documented cases. Ms. A’s
eosinophilia and elevated inflammatory mark-
ers suggest an etiology more closely aligned to
the immunoallergic reaction observed in
approximately half of the cases documented,
than with the idiosyncratic responses
described in the remainder. Our case is com-
parable with other reported cases of liver toxi-
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city in onset of symptoms (4-5 weeks following
clozapine initiation), clozapine dose (300-500
mg daily) and duration before normalization of
laboratory results (4-6 weeks), although the
LFT figures reported in Ms. A’s case surpass
those described in existing literature. It should
be noted that in many of these cases, clinical
symptoms were non-specific, as in Ms. A’s
case, or absent altogether.
The authors fully acknowledge that the
patient’s pleural effusion may have occurred
due to other etiologies, an assertion that may
have been supported by investigations
declined by Ms. A. We do, however, believe that
the close correlation of clinical symptoms with
laboratory tests and the rapid resolution of
effusion in the absence of antibiotic therapy
support an association with hepatotoxicity. It
is also noted that clozapine-induced pleural
effusion is not unprecedented in the literature.
Whilst both the unsuccessful and successful
re-challenges with clozapine therapy following
adverse reactions are documented in existing
reports,6,7,10 re-challenge was considered inap-
propriate in Ms. A’s case, given the extent of
LFT derangement and clinical symptoms.
This case supports existing literature in
advocating a high index of suspicion, particu-
larly in the 4-5 weeks following clozapine initi-
ation, when considering clinical symptoms and
signs commonly associated with other patholo-
gies. Whilst the documented prevalence of
transient LFT elevation should urge caution in
the premature cessation of clozapine therapy,
clinicians should maintain a low threshold for
monitoring such parameters following the
emergence of innocuous symptoms and signs.
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